Phase 3 Topline Data/ FDA Recommends Additional Studies
Amp Volatility Score
Catalyst Info & Data Links
NCT02624947: A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
June 10, 2019 The U.S. Food & Drug Administration (FDA) has recommended that Novavax conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease in infants born to mothers vaccinated with ResVax.
February 28, 2019: Phase 3 Topline Results